Related Experiment Video
Updated: May 20, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Children and adolescent acceptability of a new device system to administer human growth hormone--a pilot study
Anne-Marie Kappelgaard1, Søren Mikkelsen, Claus Bagger
1Growth Hormone Global Marketing, Novo Nordisk A/S, Vandtårnsvej 108-110, 2860 Søborg, Denmark. amk@novonordisk.com
Background:
Growth hormone (GH) is used to treat growth failure in children and metabolic impairments in adults with GH deficiency (GHD). Treatment requires daily subcutaneous injections that may affect treatment outcomes, and subsequently efficacy outcomes. To enhance potential adherence, improved GH delivery device systems are being developed.
Objective:
To compare patient acceptability and usability of Norditropin FlexPro/FlexPro PenMate with Norditropin NordiFlex/NordiFlex PenMate for GH administration in children/adolescents with GHD.
Methods:
A multinational, open-label, uncontrolled study. Patients (n = 50; 4-18 years) currently on GH therapy injected test medium into a foam pad. Ease-of-use and patient device preference were recorded by questionnaire.
Results:
The majority (80%) of patients preferred FlexPro PenMate over NordiFlex PenMate with 96% and 84%, respectively, reporting that they found the FlexPro PenMate system user-friendly and that they were highly confident using it.
Conclusion:
The FlexPro system was well accepted by patients. This may facilitate greater adherence to treatment and improve patient outcomes.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Dosing: Infants and Children
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hormonal Regulation
Hormonal Regulation
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

